Mikolaj Tomulewicz

Mikolaj Tomulewicz

Auto-generated profile, based on publicly available information

Mikolaj Tomulewicz

Univ Med Sci Bialystok, Krakowska 9, PL-15875 Bialystok, Poland

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 November 2023 in Acta Poloniae Pharmaceutica - Drug Research
Verified
Journal Article
Open access
AZAgnieszka Zakrzeska
Agnieszka Zakrzeska
PKPaweł Kitlas
Paweł Kitlas
ASAlexej Shlyahtun
Alexej Shlyahtun
NSNatalia Szymańska
Natalia Szymańska
RJRyszard Jabłoński
Ryszard Jabłoński
MTMikołaj Tomulewicz
Mikołaj Tomulewicz
Betulin is natural pentacyclic triterpenoids lupane-structure, which shows a wide range of biological activity, including possibly hypoglycemic effects. Diabetes mellitus is a metabolic disease, accompanied by chronic hyperglycemia caused by absolute or relative insulin deficiency. The main effective drug in the treatment of type 1 diabetes is insulin injections. In the case of type 2 diabetes, it is an adjuvant therapy. To purpose of this study was to show hypoglycemic action of betulin in a model of experimentally induced diabetes in rats. For the induction of diabetes, alloxan at a dose of 170 mg/kg, i.p. was used. The hypoglycemic effect of betulin was evaluated using doses of 50 and 100 mg/kg/day for 30 days. The activity of glucose metabolism enzymes: liver glycogen phosphorylase, hexokinase and liver and skeletal muscle phosphofructokinase in rats, glucose-6-phosphate dehydrogenase (DG-6-P) of the liver was also evaluated. Betulin in a dose-dependent manner normalized of glycemia, increased the basal insulin concentration in the blood serum, increased the activity of carbohydrate metabolizing enzymes and on the gene expression profile of enzymes involved in carbohydrate metabolism. Betulin also significant improved the morphology of the pancreas. In particular, there was an increase in the area of the islands, their diameter, an increase in the number of β cells in the composition of the islands. We conclude that betulin has hypoglycemic properties, improving glycemia and carbohydrate metabolizing enzymes and pancreatic morphology.

27 July 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
ASAlexej H Shlyahtun
Alexej H Shlyahtun
YMYu. Z. Maksimchik
Yu. Z. Maksimchik
AZAgnieszka Zakrzeska
Agnieszka Zakrzeska
ISIrina P Sutsko
Irina P Sutsko
ARAlena F. Raduta
Alena F. Raduta
YBYauheni V. Bahdzevich
Yauheni V. Bahdzevich
Type 2 diabetes mellitus (T2DM) is a complex chronic metabolic disease characterized by long-term hyperglycemia, which is, in turn, resulted from the impaired insulin signaling caused by a combination of insulin resistance or inadequate insulin production. Prevalence and incidence of T2DM are increasing dramatically across the world, and it is accompanied with severe complications and premature mortality of patients with diabetes. Given the fact that synthetic drugs have disadvantages in view of the side effects, the implementation of naturally occurring compounds for diabetes treatment may be a promising alternative. Betulin is a naturally occurring triterpenoid which has been shown to possess the ability of altering body lipids and exert hypoglycemic and hepatoprotective effects. It is suggested that the application of betulin in T2DM may have a favorable effect to ease the severity of diabetic complications. Thus, the aim of the present study was to assess biological effects of betulin in T2DM conditions. Diabetes-induced rats were administered with two different doses of betulin for 28 consecutive days. It was shown that long-term administration of betulin at the doses of 50 and 100 mg/kg/day to the rats prevented diabetes-associated changes in a body weight of the animals, significantly reversed insulin resistance and abolished the impairment of glucose metabolism. It was accompanied with the dose-dependent normalization of serum lipid contents. Histopathological changes and structural abnormalities in the liver of diabetics were restored by the administration of betulin. Also, betulin was able to restrain systemic inflammation detected in diabetic animals according to the altered levels of serum TNFα. Thus, the results obtained in the current study were found to be in agreement with earlier findings on beneficial effects of betulin in conditions pathogenetically close to T2DM. We hypothesized that the ability of betulin to restrain systemic inflammation and to normalize the lipid metabolism can explain improved insulin resistance and glycemic control and it can provide a possible mechanism for the beneficial antidiabetic effects of betulin.